The Medicines Company's EUROMAX trial of Angiox(r) (bivalirudin) in heart attack meets all prespecified endpoints

The Medicines Company (NASDAQ: MDCO) today announced results from the EUROMAX Trial, a 2,218 patient Phase IIIb randomized study of the Company's Angiox® (bivalirudin), which is marketed as Angiomax® (bivalirudin) in the US. The trial met its pre-specified primary and secondary endpoints, including statistically significant reductions in the primary composite endpoint of death and major bleeding among patients randomized to Angiox...
Source: Health News from Medical News Today - Category: Consumer Health News Tags: Cardiovascular / Cardiology Source Type: news